[go: up one dir, main page]

DK3723790T3 - Fremgangsmåder til inducering af immuntolerance og reduktion af anti-lægemiddel-antistofrespons - Google Patents

Fremgangsmåder til inducering af immuntolerance og reduktion af anti-lægemiddel-antistofrespons Download PDF

Info

Publication number
DK3723790T3
DK3723790T3 DK18889387.9T DK18889387T DK3723790T3 DK 3723790 T3 DK3723790 T3 DK 3723790T3 DK 18889387 T DK18889387 T DK 18889387T DK 3723790 T3 DK3723790 T3 DK 3723790T3
Authority
DK
Denmark
Prior art keywords
immunotolerance
induction
drug
reduction
methods
Prior art date
Application number
DK18889387.9T
Other languages
English (en)
Inventor
Naveh Tov
Original Assignee
Kamada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kamada Ltd filed Critical Kamada Ltd
Application granted granted Critical
Publication of DK3723790T3 publication Critical patent/DK3723790T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/001Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18889387.9T 2017-12-12 2018-12-10 Fremgangsmåder til inducering af immuntolerance og reduktion af anti-lægemiddel-antistofrespons DK3723790T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597441P 2017-12-12 2017-12-12
PCT/IL2018/051342 WO2019116367A1 (en) 2017-12-12 2018-12-10 Methods of inducing immune tolerance and reducing anti-drug antibody response

Publications (1)

Publication Number Publication Date
DK3723790T3 true DK3723790T3 (da) 2024-04-22

Family

ID=66820781

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18889387.9T DK3723790T3 (da) 2017-12-12 2018-12-10 Fremgangsmåder til inducering af immuntolerance og reduktion af anti-lægemiddel-antistofrespons

Country Status (10)

Country Link
US (1) US20210008183A1 (da)
EP (1) EP3723790B1 (da)
CA (1) CA3085696A1 (da)
DK (1) DK3723790T3 (da)
ES (1) ES2984415T3 (da)
FI (1) FI3723790T3 (da)
IL (1) IL275328B2 (da)
PL (1) PL3723790T3 (da)
PT (1) PT3723790T (da)
WO (1) WO2019116367A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2757875C1 (ru) * 2020-11-13 2021-10-22 Генфа Глобал Лб (Лабораторис Биофармасьютика) Са Применение ингибитора альфа1-протеиназы (альфа1-антитрипсина) для профилактики и/или лечения острого респираторного дистресс синдрома и способ профилактики и/или лечения острого респираторного дистресс синдрома с использованием альфа1-антитрипсина

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
WO1986000337A1 (fr) 1984-06-19 1986-01-16 Transgene S.A. DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US5093316A (en) 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
EE200000546A (et) 1998-03-16 2002-02-15 Inhale Therapeutic Systems, Inc. Aerosoolistatud toimeaine manustamissüsteem
DK1071806T3 (da) * 1998-04-24 2004-07-19 Univ Florida Rekombinant adeno-associeret virus-vektor, der koder for alpha-1-antitrypsin i genterapi
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
WO2004024655A2 (en) * 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
ATE391730T1 (de) 2003-09-22 2008-04-15 Kamada Ltd Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
CA2641872A1 (en) * 2006-02-09 2007-08-16 Kamada Ltd. Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
WO2018154568A1 (en) * 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases

Also Published As

Publication number Publication date
IL275328B1 (en) 2023-11-01
US20210008183A1 (en) 2021-01-14
PL3723790T3 (pl) 2024-05-13
PT3723790T (pt) 2024-05-10
EP3723790A1 (en) 2020-10-21
IL275328B2 (en) 2024-03-01
CA3085696A1 (en) 2019-06-20
FI3723790T3 (fi) 2024-04-19
ES2984415T3 (es) 2024-10-29
EP3723790B1 (en) 2024-03-13
IL275328A (en) 2020-07-30
WO2019116367A1 (en) 2019-06-20
EP3723790A4 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
DK3750418T3 (da) Aerosolgenereringsenhed og fremgangsmåde til styring af samme
DK3601358T5 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
EP3634430A4 (en) MULTIBIOTIC AGENTS AND METHODS OF USE THEREOF
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3377612T3 (da) Funktionel ekspression af monooxygenaser og fremgangsmåder til anvendelse
DK3701973T3 (da) Plasmabaseret film og fremgangsmåder til fremstilling og anvendelse af samme
DK3430378T3 (da) Indretninger og fremgangsmåder til modifikation af optiske egenskaber
DK3426781T3 (da) Mikro-rna'er og fremgangsmåder til anvendelse deraf
DK3350201T3 (da) Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3529257T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK4105223T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3398022T3 (da) Systemer og fremgangsmåder til tilpasning af uav-bane
DK3548033T3 (da) Forbindelser og deres fremgangsmåde til anvendelse
DK3289168T3 (da) Forsegling og aktivering af borehul
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3035532T3 (da) Gatedriverkredsløb og fremgangsmåde til betjening af samme
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3551209T3 (da) Insulin-fc-fusioner og fremgangsmåder til anvendelse
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3426777T3 (da) Kombinationsvektorer og fremgangsmåder til behandling af cancer